In conclusion, a population of advanced/metastatic melanoma patients, of whom 33% had BRAF mutation, 43% were PD-L1 positive, and 41% had prior systemic therapy, were followed up for approximately for 26 months, and pembrolizumab treatment either alone or in combination with other agents led to the ORR, PFS, and OS of approximately 34%, 5.7 months, and 20.3 months, respectively, all of which were higher in treatment in naïve patients. Here, BRAF is linked to metastatic melanoma.